Holen Sie sich die Stockscreener-App
33.70
1.02%
0.34
Handel nachbörslich:
33.70
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$33.36
Offen:
$33.68
24-Stunden-Volumen:
2.67M
Relative Volume:
0.58
Marktkapitalisierung:
$17.29B
Einnahmen:
$17.28B
Nettoeinkommen (Verlust:
$108.00M
KGV:
168.50
EPS:
0.2
Netto-Cashflow:
$391.00M
1W Leistung:
+0.78%
1M Leistung:
-3.99%
6M Leistung:
-13.39%
1J Leistung:
-21.06%
1-Tages-Spanne:
$33.31
$33.91
1-Wochen-Bereich:
$32.80
$33.91
52-Wochen-Spanne:
$28.34
$43.99
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(847) 948-2000
Adresse
ONE BAXTER PKWY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
33.70 | 17.29B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
507.90 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.71 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
96.80 | 45.17B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
222.62 | 32.70B | 4.93B | 1.25B | 1.38B | 8.47 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Peering Into Baxter Intl's Recent Short Interest - Benzinga
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Is Baxter International Stock Underperforming the S&P 500? - Nasdaq
Baxter Announces All-Digital Shareholder Meeting: How to Participate Virtually - StockTitan
Is Baxter International Stock Underperforming The S&P 500? - Barchart
KLP Kapitalforvaltning AS Invests $5.10 Million in Baxter International Inc. (NYSE:BAX) - MarketBeat
Sound Shore Management Inc. CT Invests $72.45 Million in Baxter International Inc. (NYSE:BAX) - MarketBeat
Parenteral Nutrition Research Analysis 2024: A Global $13.6 Billion Market by 2029, Driven by Increased Utilization of Premixed PN Formulations and Growing Preference for Home Parenteral Nutrition - GlobeNewswire Inc.
Short Interest in Baxter International Inc. (NYSE:BAX) Expands By 17.7% - MarketBeat
Baxter International: Navigating Leadership Transition and Market Growth Amidst Tariff Challenges - TipRanks
Tredje AP fonden Sells 39,465 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Update on Alert: Infusion Pump Issue from Baxter Healthcare Corporati - FDA.gov
Thompson Siegel & Walmsley LLC Boosts Stake in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter Wins Some Relief on Nevakar Blood-Pressure Drug Patents - Bloomberg Law
Here’s Why Baxter International (BAX) Fell in Q4 - Insider Monkey
Amundi Raises Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Carlyle Agrees to Buy Baxter’s Kidney Care Business for $3.8B - DocWire News
Baxter International Inc. (NYSE:BAX) Shares Sold by Cooke & Bieler LP - MarketBeat
Baxter International (BAX) Engages Stockholders with New Presentation - GuruFocus.com
Baxter International Appoints New Leadership Amid Strategic Changes - TipRanks
Baxter International (NYSE:BAX) Price Target Raised to $41.00 at Barclays - MarketBeat
E Fund Management Co. Ltd. Acquires Shares of 11,641 Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International’s SWOT analysis: medical supplies stock shows resilience - Investing.com
Baxter International’s SWOT analysis: medical supplies stock shows resilience By Investing.com - Investing.com South Africa
Baxter at Barclays Healthcare Conference: Strategic Focus on Growth - Investing.com
Baxter International Inc. (NYSE:BAX) Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Medical Specialty Bags Market Set to Witness Significant Growth by 2025-2032: Braun Melsungen AG, Baxter - EIN News
June 2026 Options Now Available For Baxter International (BAX) - Nasdaq
Baxter (BAX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Baxter (BAX): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.34%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):